Ticker: NUVL

Nuvalent, Inc. (NASDAQ: NUVL) is navigating a critical phase as a clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer. Despite the potential of its lead product candidates, the company is grappling with significant financial challenges and operational hurd...